Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Glaxosmithkline (GSK) Share News

GSK drug momelotinib gains regulatory nods as VEXAS treatment

12th Jun 2026 10:05

(Alliance News) - GSK PLC on Friday announced that momelotinib has received orphan drug designation from the US Food & Drug Administration, and the European Medicines Agency, to treat VEXAS syndrome. Read More

LONDON BRIEFING: UK economy contracts in April; Flutter to leave LSE

12th Jun 2026 07:58

(Alliance News) - The UK economy contracts 0.1% in April, Flutter Entertainment says it will delist from the London Stock Exchange in August, while Alternative Income REIT's largest shareholder makes a takeover bid. Read More

LONDON MARKET MIDDAY: FTSE 100 lags Europe as oil majors, GSK weigh

9th Jun 2026 12:10

(Alliance News) - Stock prices in London were mixed at midday on Tuesday, as the FTSE 100 lagged European peers despite renewed optimism for a peace deal in the Middle East, as oil majors and GSK weighed on the blue-chip index. Read More

WINNERS & LOSERS: GSK falls after Nuvalent buy; Molten Ventures jumps

9th Jun 2026 10:34

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Tuesday. Read More

LONDON MARKET OPEN: FTSE 100 down as GSK buys US drugmaker Nuvalent

9th Jun 2026 09:09

(Alliance News) - Stock prices in London opened mixed on Tuesday, as the FTSE 100 fell after GSK agreed to buy US-based cancer drug developer Nuvalent for USD10.6 billion. Read More

UPDATE: GSK buys cancer drug developer Nuvalent for USD10.6 billion

9th Jun 2026 09:00

(Alliance News) - GSK PLC on Tuesday said it has agreed to US-based cancer drug developer Nuvalent Inc for USD10.6 billion. Read More

LONDON BRIEFING: GSK agrees to buy US cancer drug maker Nuvalent

9th Jun 2026 07:58

(Alliance News) - GSK agrees to buy US cancer treatment firm Nuvalent for USD10.6 billion, AstraZeneca advances its own weight-loss treatment while Bellway reports an "increasingly challenging" housing market. Read More

LONDON MARKET EARLY CALL: FTSE 100 to rise as Israel, Iran end attacks

9th Jun 2026 06:51

(Alliance News) - Stocks in London are set to open slightly higher on Tuesday, after Iran and Israel said they would end recent hostilities that had threatened peace talks. Read More

GSK hails "major step forward" after "positive" hepatitis drug results

28th May 2026 10:57

(Alliance News) - GSK PLC on Thursday reported "positive" phase 3 trial data for its hepatitis B treatment, Bepirovirsen, which it said could "redefine" treatment for the disease. Read More

GSK's RSV vaccine Arexvy approved in Japan for some adults under 50

18th May 2026 08:36

(Alliance News) - GSK PLC on Monday announced that Japan's Ministry of Health, Labour & Welfare expanded the eligible population for its respiratory syncytial virus vaccine Arexvy. Read More

WINNERS & LOSERS: Miners slide; Centrica to pay GBP20 million to Ofgem

15th May 2026 10:30

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Friday. Read More

GSK agrees China hepatitis B deal as kicks off last tranche of buyback

11th May 2026 08:26

(Alliance News) - GSK PLC on Monday launched the fifth tranche of its GBP2.0 billion buyback as it announced an exclusive collaboration with China pharmaceutical group Sino Biopharmaceutical Ltd. Read More

LONDON BRIEFING: Compass lifts outlook as GSK expands in China

11th May 2026 07:56

(Alliance News) - Compass Group raised annual profit guidance after reporting double-digit first-half operating profit growth, while GSK announced a China partnership for hepatitis B treatment bepirovirsen and the final tranche of its GBP2 billion buyback. Elsewhere, Victrex warned higher energy costs linked to the Middle East conflict could weigh on demand as interim profit declined. Read More

FTSE 100 Latest

Value10,471.72

Change167.84